Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.
A diabetes drug prevents type 2 diabetes development in women with recent gestational diabetes, a high-risk population.
INTRODUCTION: Women with postpartum pre-diabetes following gestational diabetes mellitus (GDM) are at particularly high risk of developing type 2 diabetes mellitus (T2DM). TRIAL REGISTRATION NUMBER: NCT05569772.
What the study was
- Study design
- Randomized study
- Population
- patients
- Sample size
- 252
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- BMJ open
Why it surfaced
Score 6/10 [PROMISING_PRELIMINARY]: Randomized study (Journal Article) matched 'Cardiovascular-metabolic: GLP-1, SGLT2, '. Components — novelty:1/3, relevance:2/3, design:2/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.